Treatment of prostatic cancer, breast cancer, and endomertriosis; it may be useful in other conditions, including uterine leiomyomata.

Goserelin is a synthetic analogue of gonadotropin releasing hormone (GnRH, LH-RH) use of continuous therapeutic doses results in prolonged suppression of pituitory gonadotropins and gonadal steroid production. It is usefulness as an alternative to estrogen therapy or orchiectomy for the palliation of advanced carcinoma of the prostate. In endometriosis, goserelin has been shown to be at least as effective as danazol.

Hypersensitivity to goserelin, leutenizing hormone-releasing hormone (LH-RH) or LHRH agonist analogues, pregnant women, women who may become pregnant during therapy.

X for treatment of endometriosis / D for treatment of advance breast cancer in pre- and perimenopausal women.

transient exacerbation of the tumor with subsequent bone pain, hot flashes, decreased libido, gynecomastia, and impotence.

Goserelin is injected as a subcutaneous implant; the 3.6 mg implant is administered every 28 days.